Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus PT from Analysts
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Metagenomi (MGX) to Release Earnings on Wednesday
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus Target Price from Analysts
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript
Hiab expands US footprint with appointment of MGX Equipment Services as new dealer in 13 states
Metagenomi (NASDAQ:MGX) Shares Down 1.2% – Here’s Why
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages
Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Metagenomi (NASDAQ:MGX)
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Metagenomi to Present at Jefferies Global Healthcare Conference in London
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
Metagenomi taps Amazon's custom chips to develop gene-editing tools
Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy
Meet MGX: The UAE's sovereign wealth fund working with TikTok, Microsoft and BlackRock
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
Metagenomi Announces New Appointment to its Board of Directors
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. - MGX
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX
Contact Levi & Korsinsky by November 25, 2024 Deadline to Join Class Action Against Metagenomi, Inc. (MGX)
Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm